Opella secures non-prescription approval of Cialis in Norway

Paris, September 3^rd, 2025 – Opella announces the non-prescription approval of Cialis reseptfri (tadalafil 10mg) in Norway. This milestone facilitates access to a self-care solution with proven effectiveness for men living with erectile dysfunction (ED) in Norway and reinforces Opella’s mission to simplify health solutions.  

 ED is a common yet often under-discussed condition. Across the European Union, the overall prevalence of ED is estimated at 42%.¹ In Norway, this equates to hundreds of thousands of individuals who could benefit from increased access to effective treatment options. The launch, in partnership with STADA, is currently being planned and the medicine will soon be on shelves in Norway.

 Dr Josephine Fubara, Chief Science Officer at Opella:

“This medicine’s approval in Norway for non-prescription status marks an important regulatory milestone. This demonstrates Opella’s commitment to innovative health solutions that empower individuals. By making this drug available over the counter, Opella continues to champion a consumer-first and science-backed approach to healthcare.”

 For Opella, non-prescription switch is a strategic growth driver, on par with product innovation and international brand expansion. Each switch requires the submission of a comprehensive dossier to national health authorities, often including real-world usage data to evaluate the product's safety profile under everyday conditions. This rigorous approach ensures that self-care solutions meet high standards of efficacy and consumer safety. By pursuing well-targeted switches such as this medicine in Norway, Opella advances its commitment to simplifying healthcare and expanding access to trusted treatments.